Dr James Good

MSc PhD FRCR


Special clinical interest in colon (bowel), head/neck, liver, pancreas, rectum, thyroid. Selective internal radiotherapy (SIRT) for liver tumours. Radiotherapy for recurrent and secondary cancer.

LANGUAGES

English

Professional profile

Dr Good is the local lead clinician on several clinical trials investigating both immunotherapy and novel radiation techniques. He has a particular interest in novel drug/radiotherapy combinations; Dr Good sits on the trial management group of the phase 3 CompARE trial, investigating immunotherapy in combination with radiotherapy, and is deputy chief investigator of the WISTERIA trial, which investigates a DNA damage response modulator with radiotherapy.

After training as a scientist at Cambridge University, Dr Good trained in medicine at University College, London. After clinical training in London and Oxford he spent six years at the Royal Marsden and Guy’s Hospitals developing expertise in intensity-modulated radiotherapy (IMRT), image-guided radiotherapy (IGRT) and stereotactic radiotherapy (SBRT).

Dr Good focuses on innovative, personalized treatment of cancers of the bowel, head/neck and thyroid using chemotherapy, radiotherapy, targeted therapy, and immunotherapy. He also specializes in advanced radiation technique for liver and pancreatic tumours, secondary tumours, and recurrent cancer. He was the first oncologist in the Midlands to treat head/neck cancer with the most promising form of immunotherapy, and the first to treat liver tumours with CyberKnife and high dose VMAT radiotherapy.

Current NHS post
Consultant Clinical Oncologist, Queen Elizabeth Hospital, Birmingham

Year qualified
2004

Professional memberships
Fellow, Royal College of Radiologists.
Member, Royal College of Physicians.
Member, Radiosurgery Society.
Member, European Society of Medical Oncology.
Research interests
Dr Good is the local lead clinician on several clinical trials investigating both immunotherapy and novel radiation techniques. He has a particular interest in novel drug/radiotherapy combinations; Dr Good sits on the trial management group of the phase 3 CompARE trial, investigating immunotherapy in combination with radiotherapy, and is deputy chief investigator of the WISTERIA trial, which investigates a DNA damage response modulator with radiotherapy.

Contact details
Secretary: Sheena Colline
Tel: 0121 371 3599
Email: sheena.collins@uhb.nhs.uk
Website: https://drjamesgood.com

Private clinic information
•Monday, 18:00-20:00: Spire Little Aston Hospital
•Tuesday, 18:00-20:00: BMI Priory Hospital, Edgbaston
•Thursday, 18:00-20:00: Spire Parkway Hospital, Solihull

Specialities

  • Oncology

Centres